Correlation Between Inhibikase Therapeutics and Day One
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Day One at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Day One into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and Day One Biopharmaceuticals, you can compare the effects of market volatilities on Inhibikase Therapeutics and Day One and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Day One. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Day One.
Diversification Opportunities for Inhibikase Therapeutics and Day One
0.63 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Inhibikase and Day is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Day One Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Day One Biopharmaceu and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Day One. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Day One Biopharmaceu has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Day One go up and down completely randomly.
Pair Corralation between Inhibikase Therapeutics and Day One
Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 1.83 times more return on investment than Day One. However, Inhibikase Therapeutics is 1.83 times more volatile than Day One Biopharmaceuticals. It trades about 0.02 of its potential returns per unit of risk. Day One Biopharmaceuticals is currently generating about -0.01 per unit of risk. If you would invest 335.00 in Inhibikase Therapeutics on August 26, 2024 and sell it today you would lose (104.00) from holding Inhibikase Therapeutics or give up 31.04% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inhibikase Therapeutics vs. Day One Biopharmaceuticals
Performance |
| Timeline |
| Inhibikase Therapeutics |
| Day One Biopharmaceu |
Inhibikase Therapeutics and Day One Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibikase Therapeutics and Day One
The main advantage of trading using opposite Inhibikase Therapeutics and Day One positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Day One can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will offset losses from the drop in Day One's long position.| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
| Day One vs. Eliem Therapeutics | Day One vs. HCW Biologics | Day One vs. Scpharmaceuticals | Day One vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Complementary Tools
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |